Last reviewed · How we verify

NCT06081088

Graded Motor Imagery Training in Shoulder Impingement Syndrome

Completed NA Last updated 28 June 2024
What this trial tests

NA trial testing Graded Motor Imagery (GMI) training in Shoulder Impingement Syndrome in 42 participants. Completed in 27 June 2024.

Timeline
16 October 2023
Primary endpoint
27 June 2024
27 June 2024

Quick facts

Lead sponsorMarmara University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment42
Start date16 October 2023
Primary completion27 June 2024
Estimated completion27 June 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Marmara University

Who can join

Adults 25 to 65, any sex, with Shoulder Impingement Syndrome or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the effects of Graded Motor Imagery (GMI) training on pain, functionality, disability and daily living activities in patients diagnosed with Shoulder Impingement Syndrome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The effectiveness of graded motor imagery training on pain and functionality in patients with subacromial pain syndrome: A prospective, single-blind, randomized controlled trial.
    Amir Rashedi Bonab M, Kuru Colak T, Colak I, Ozdamar I. · · 2026 · cited 1× · PMID 40371015 · DOI 10.1177/17585732251340327

Verify or expand the search:

Other recruiting trials for Shoulder Impingement Syndrome

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06081088.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing